Evidence map›Paper›PMID 33353250›Full record

ArticleInternational journal of environmental research and public health2020

Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries.

Katrina Perehudoff, Ivan Demchenko, Nikita V Alexandrov, David Brutsaert, Angela Ackon, Carlos E Durán, Faris El-Dahiyat, Firdaus Hafidz, Rezwan Haque, Rabia Hussain and 3 more

Abstract readScoping Review
In one paragraph

Article in International journal of environmental research and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Universal health coverage and COVID-19: recent developments and implications.Journal of pharmaceutical policy and practice · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Katrina PerehudoffLaw Center for Health and Life, University of Amsterdam, 1018 WV Amsterdam, The Netherlands.
Ivan DemchenkoForensic Medicine and Medical Law Department, National Medical University 'O.O. Bogomolec', 01601 Kyiv, Ukraine.ORCID 0000-0001-8721-2775
Nikita V AlexandrovGlobal Health Law Groningen Research Centre, Department of Transboundary Legal Studies, Faculty of Law, University of Groningen, 9700 AS Groningen, The Netherlands.ORCID 0000-0001-5526-532X
David BrutsaertDepartment of Public Health & Primary Care, Ghent University, 9000 Gent, Belgium.ORCID 0000-0002-6383-6230
Angela AckonDirectorate of Pharmacy, Ministry of Health, P. O. Box M 44 Accra, Ghana.
Carlos E DuránClinical Pharmacology Research Group, Department of Basic & Applied Medical Sciences, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0003-1853-3641
Faris El-DahiyatCollege of Pharmacy, Al Ain University, 64141 Al Ain, UAE.ORCID 0000-0002-5264-8699
Firdaus HafidzDepartment of Health Policy & Management, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.ORCID 0000-0002-1787-4930
Rezwan HaqueAccess to Information (a2i) Programme (Former Project Director, SWASTI), Dhaka 1207, Bangladesh.
Rabia HussainFaculty of Pharmacy, The University of Lahore, Lahore 54590, Pakistan.ORCID 0000-0001-8183-0855
Roderick SalengaCollege of Pharmacy, University of the Philippines Manila, Metro Manila 1000, Philippines.
Fatima SulemanDiscipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban 4041, South Africa.ORCID 0000-0002-8559-9168
Zaheer-Ud-Din BabarDepartment of Pharmacy, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.ORCID 0000-0003-1051-3240

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Very few studies exist of legal interventions (national laws) for essential medicines as part of universal health coverage in middle-income countries, or how the effect of these laws is measured. This study aims to critically assess whether laws related to universal health coverage use five objectives of public health law to promote medicines affordability and financing, and to understand how access to medicines achieved through these laws is measured. This comparative case study of five middle-income countries (Ecuador, Ghana, Philippines, South Africa, Ukraine) uses a public health law framework to guide the content analysis of national laws and the scoping review of empirical evidence for measuring access to medicines. Sixty laws were included. All countries write into national law: (a) health equity objectives, (b) remedies for users/patients and sanctions for some stakeholders, (c) economic policies and regulatory objectives for financing (except South Africa), pricing, and benefits selection (except South Africa), (d) information dissemination objectives (ex. for medicines prices (except Ghana)), and (e) public health infrastructure. The 17 studies included in the scoping review evaluate laws with economic policy and regulatory objectives (

Indexed as

Diabetes Mellitus, Type 2Universal Health InsuranceAdultCross-Sectional StudiesDeveloping CountriesEcuadorGhanaHealth Care ReformHealth Services AccessibilityHumansLongitudinal StudiesPhilippinesPublic HealthRetrospective StudiesSouth AfricaUkraineaccess to medicinesdrugessential medicineshealth insurancehealth services accessibilityinsurancelegislationmiddle income countrypharmaceutical policypharmaceutical servicesuniversal health coverageuniversal health insurance

Identifiers

PMID33353250
PMCPMC7765934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.